Cargando…
Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
BACKGROUND: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. METHODS: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342934/ https://www.ncbi.nlm.nih.gov/pubmed/34377969 http://dx.doi.org/10.1016/j.eclinm.2021.101069 |
_version_ | 1783734168980553728 |
---|---|
author | Francischetti, Ivo M.B. Toomer, Kevin Zhang, Yifan Jani, Jayesh Siddiqui, Zishan Brotman, Daniel J. Hooper, Jody E. Kickler, Thomas S. |
author_facet | Francischetti, Ivo M.B. Toomer, Kevin Zhang, Yifan Jani, Jayesh Siddiqui, Zishan Brotman, Daniel J. Hooper, Jody E. Kickler, Thomas S. |
author_sort | Francischetti, Ivo M.B. |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. METHODS: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020. Markers of coagulation, endothelial cell function [angiopoietin-1,-2, P-selectin, von Willebrand Factor Antigen (WF:Ag), von Willebrand Factor Ristocetin Cofactor, ADAMTS13, thrombomodulin, soluble Endothelial cell Protein C Receptor (sEPCR), Tissue Factor Pathway Inhibitor], neutrophil activation (elastase, citrullinated histones) and fibrinolysis (tissue-type plasminogen activator, plasminogen activator inhibitor-1) were evaluated using ELISA. Tissue Factor (TF) was estimated by antithrombin-FVIIa complex (AT/FVIIa) and microparticles-TF (MP-TF). We correlated each marker and determined its association with severity. Expression of pulmonary TF, thrombomodulin and EPCR was determined by immunohistochemistry in 9 autopsies. FINDINGS: Comorbidities were frequent in both groups, with older age associated with severe disease. All patients were on prophylactic anticoagulants. Three patients (4.5%) developed pulmonary embolism. Mortality was 7.5%. Patients presented with mild alterations in the coagulogram (compensated state). Biomarkers of endothelial cell, neutrophil activation and fibrinolysis were elevated in severe vs moderate disease; AT/FVIIa and MP-TF levels were higher in severe patients. Logistic regression revealed an association of D-dimers, angiopoietin-1, vWF:Ag, thrombomodulin, white blood cells, absolute neutrophil count (ANC) and hemoglobin levels with severity, with ANC and vWF:Ag identified as independent factors. Notably, postmortem specimens demonstrated epithelial expression of TF in the lung of fatal COVID-19 cases with loss of thrombomodulin staining, implying in a shift towards a procoagulant state. INTERPRETATION: Coagulation dysregulation has multifactorial etiology in SARS-Cov-2 infection. Upregulation of pulmonary TF with loss of thrombomodulin emerge as a potential link to immunothrombosis, and therapeutic targets in the disease. FUNDING: John Hopkins University School of Medicine. |
format | Online Article Text |
id | pubmed-8342934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83429342021-08-06 Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection Francischetti, Ivo M.B. Toomer, Kevin Zhang, Yifan Jani, Jayesh Siddiqui, Zishan Brotman, Daniel J. Hooper, Jody E. Kickler, Thomas S. EClinicalMedicine Research Paper BACKGROUND: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. METHODS: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020. Markers of coagulation, endothelial cell function [angiopoietin-1,-2, P-selectin, von Willebrand Factor Antigen (WF:Ag), von Willebrand Factor Ristocetin Cofactor, ADAMTS13, thrombomodulin, soluble Endothelial cell Protein C Receptor (sEPCR), Tissue Factor Pathway Inhibitor], neutrophil activation (elastase, citrullinated histones) and fibrinolysis (tissue-type plasminogen activator, plasminogen activator inhibitor-1) were evaluated using ELISA. Tissue Factor (TF) was estimated by antithrombin-FVIIa complex (AT/FVIIa) and microparticles-TF (MP-TF). We correlated each marker and determined its association with severity. Expression of pulmonary TF, thrombomodulin and EPCR was determined by immunohistochemistry in 9 autopsies. FINDINGS: Comorbidities were frequent in both groups, with older age associated with severe disease. All patients were on prophylactic anticoagulants. Three patients (4.5%) developed pulmonary embolism. Mortality was 7.5%. Patients presented with mild alterations in the coagulogram (compensated state). Biomarkers of endothelial cell, neutrophil activation and fibrinolysis were elevated in severe vs moderate disease; AT/FVIIa and MP-TF levels were higher in severe patients. Logistic regression revealed an association of D-dimers, angiopoietin-1, vWF:Ag, thrombomodulin, white blood cells, absolute neutrophil count (ANC) and hemoglobin levels with severity, with ANC and vWF:Ag identified as independent factors. Notably, postmortem specimens demonstrated epithelial expression of TF in the lung of fatal COVID-19 cases with loss of thrombomodulin staining, implying in a shift towards a procoagulant state. INTERPRETATION: Coagulation dysregulation has multifactorial etiology in SARS-Cov-2 infection. Upregulation of pulmonary TF with loss of thrombomodulin emerge as a potential link to immunothrombosis, and therapeutic targets in the disease. FUNDING: John Hopkins University School of Medicine. Elsevier 2021-08-06 /pmc/articles/PMC8342934/ /pubmed/34377969 http://dx.doi.org/10.1016/j.eclinm.2021.101069 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Francischetti, Ivo M.B. Toomer, Kevin Zhang, Yifan Jani, Jayesh Siddiqui, Zishan Brotman, Daniel J. Hooper, Jody E. Kickler, Thomas S. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title | Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title_full | Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title_fullStr | Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title_full_unstemmed | Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title_short | Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection |
title_sort | upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in sars-cov-2 infection |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342934/ https://www.ncbi.nlm.nih.gov/pubmed/34377969 http://dx.doi.org/10.1016/j.eclinm.2021.101069 |
work_keys_str_mv | AT francischettiivomb upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT toomerkevin upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT zhangyifan upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT janijayesh upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT siddiquizishan upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT brotmandanielj upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT hooperjodye upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection AT kicklerthomass upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection |